Corcept Begin Period Cash Flow from 2010 to 2024
| CORT Stock | USD 30.17 1.04 3.33% |
Begin Period Cash Flow | First Reported 2003-03-31 | Previous Quarter 111.8 M | Current Value 135.6 M | Quarterly Volatility 42.1 M |
Check Corcept Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corcept main balance sheet or income statement drivers, such as Interest Expense of 4.3 M, Selling General Administrative of 193.1 M or Research Development of 193.6 M, as well as many exotic indicators such as Price To Sales Ratio of 6.62, Dividend Yield of 0.0 or PTB Ratio of 6.97. Corcept financial statements analysis is a perfect complement when working with Corcept Therapeutics Valuation or Volatility modules.
Corcept | Begin Period Cash Flow |
Latest Corcept Therapeutics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Corcept Therapeutics Incorporated over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Corcept Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Corcept Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Corcept Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 47,339,830 | |
| Geometric Mean | 42,718,749 | |
| Coefficient Of Variation | 46.86 | |
| Mean Deviation | 18,072,269 | |
| Median | 40,435,000 | |
| Standard Deviation | 22,182,323 | |
| Sample Variance | 492.1T | |
| Range | 74.6M | |
| R-Value | 0.34 | |
| Mean Square Error | 468.3T | |
| R-Squared | 0.12 | |
| Significance | 0.21 | |
| Slope | 1,691,579 | |
| Total Sum of Squares | 6888.8T |
Corcept Begin Period Cash Flow History
About Corcept Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Corcept Therapeutics income statement, its balance sheet, and the statement of cash flows. Corcept Therapeutics investors use historical funamental indicators, such as Corcept Therapeutics's Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Corcept Therapeutics investors may use each financial statement separately, they are all related. The changes in Corcept Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Corcept Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Corcept Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Corcept Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 66.3 M | 39.3 M |
Pair Trading with Corcept Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corcept Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corcept Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Corcept Stock
| 0.86 | NPCE | Neuropace | PairCorr |
| 0.61 | PPERY | Bank Mandiri Persero | PairCorr |
| 0.58 | FNA | Paragon 28 | PairCorr |
| 0.58 | PPERF | Bank Mandiri Persero | PairCorr |
| 0.54 | BKRKY | Bank Rakyat | PairCorr |
The ability to find closely correlated positions to Corcept Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corcept Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corcept Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corcept Therapeutics Incorporated to buy it.
The correlation of Corcept Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corcept Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corcept Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corcept Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Corcept Therapeutics Correlation against competitors. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Corcept Stock analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Corcept Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corcept Therapeutics. If investors know Corcept will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corcept Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.786 | Earnings Share 1.04 | Revenue Per Share 5.118 | Quarterly Revenue Growth 0.39 | Return On Assets 0.1197 |
The market value of Corcept Therapeutics is measured differently than its book value, which is the value of Corcept that is recorded on the company's balance sheet. Investors also form their own opinion of Corcept Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Corcept Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corcept Therapeutics' market value can be influenced by many factors that don't directly affect Corcept Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corcept Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corcept Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corcept Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.